骨髓瘤中性肿瘤演化与不良预后相关
研究分析Myeloma XI试验333例和CoMMpass研究434例接受免疫调节药物治疗的多发性骨髓瘤患者全外显子测序数据,发现17%至20%的骨髓瘤处于中性演化动力学,此类肿瘤在非强化治疗患者中与较差生存相关,与免疫调节药物疗效降低一致。
要点
- 17%至20%的多发性骨髓瘤处于中性演化动力学。
- 中性演化肿瘤在非强化治疗患者中与较差生存相关。
- 该结果与微环境调节性免疫调节药物疗效降低一致。
核心结论
- 骨髓瘤中性演化动力学与不良预后相关,尤其在非强化治疗患者中。
- 了解骨髓瘤演化历史有助于预测患者结局和个体化治疗。
研究设计与样本
- 分析Myeloma XI试验333例和CoMMpass研究434例接受免疫调节药物治疗的多发性骨髓瘤患者全外显子测序肿瘤数据。
主要发现
- 通过分析肿瘤突变等位基因频率分布,发现17%至20%的多发性骨髓瘤处于中性演化动力学。
- 中性演化肿瘤在非强化治疗患者中与较差生存相关,与微环境调节性免疫调节药物疗效降低一致。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcomes, we analyzed whole exome sequencing tumor data for 333 patients from Myeloma XI, a UK phase 3 trial and 434 patients from the CoMMpass study, all of which had received immunomodulatory drug (IMiD) therapy. By analyzing mutant allele frequency distributions in tumors, we found that 17% to 20% of MM is under neutral evolutionary dynamics. These tumors are associated with poorer patient survival in nonintensively treated patients, which is consistent with the reduced therapeutic efficacy of microenvironment-modulating IMiDs. Our findings provide evidence that knowledge of the evolutionary history of MM has relevance for predicting patient outcomes and personalizing therapy.
引用
- Johnson DC, Lenive O, Mitchell J, et al. Neutral tumor evolution in myeloma is associated with poor prognosis. Blood. 2017. PMID: 28827410. doi:10.1182/blood-2016-11-750612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。